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Muscular dystrophy (MD) connotes a heterogeneous group of inherited disorders
characterized by progressive wasting and weakness of the skeletal muscles. In several forms
of MD, cardiac dysfunction occurs and cardiac disease may even be the predominant
manifestation of the underlying genetic myopathy. Cardiologists may be unfamiliar with
these diseases due to low incidence; also, significant advances in respiratory care have only
recently unmasked cardiomyopathy as a significant cause of death in MD1.
Early detection of MD-associated cardiomyopathy is important, since institution of
cardioprotective medical therapies may slow adverse cardiac remodeling and attenuate heart
failure symptoms in these patients2–6. Although electrocardiography (ECG) and
echocardiography are typically advocated for screening7, 8, cardiovascular magnetic
resonance (CMR) has shown promise in revealing early cardiac involvement when standard
cardiac evaluation is unremarkable9, 10.
This review will focus on four groups of skeletal muscle disease most commonly associated
with cardiac complications (Table): 1) dystrophin-associated diseases such as Duchenne and
Becker muscular dystrophy, 2) Emery-Dreifuss muscular dystrophy, 3)limb-girdle muscular
dystrophy and 4) myotonic dystrophy.
I. Dystrophin-Associated Muscular Dystrophies
I.1 Molecular and Genetic Features
Duchenne and Becker muscular dystrophy (DMD and BMD, respectively) are X-linked
disorders affecting the synthesis of dystrophin, a large sarcolemmal protein that is absent in
DMD11 and reduced in amount or abnormal in size in BMD patients12. Dystrophin provides
the connection between a large multimeric complex of glycoproteins in the muscle cell
membrane (termed the dystrophin-glycoprotein complex, DGC) and intracellular actin
filaments (Fig. 1), thereby transmitting forces generated by sarcomere contraction to the
extracellular matrix13, 14. Correlations between dystrophin mutations and onset of
cardiomyopathy have been noted15; some mutations result in only cardiomyopathy without
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skeletal myopathy16. Other proteins not shown in Fig. 1 that are particularly involved in
both inside-out and outside-in transmission between the myocyte and the extracellular
matrix include vinculin and talin; ongoing investigations are further defining their role in
cardiomyopathies, particularly those associated with muscular dystrophies.
Dystrophin has an important role in stabilizing the cell membrane of both skeletal and
cardiac myocytes17, 18, and its absence produces sarcolemmal fragility and muscle cell
degeneration. Dystrophin deficiency may also lead to conformational changes in stretch-
activated calcium channels, resulting in pathologic leakage of calcium in the muscle
cytosol19. Intracellular calcium accumulation then leads to protease activation, increased
reactive oxygen species production and cell death20, 21. Finally, impaired vasoregulation
occurs via marked reduction in membrane-associated neuronal nitric oxide synthase (nNOS,
Fig. 1) in both cardiac and skeletal muscle22. Without dystrophin, nNOS mislocalizes to the
cytosol; this greater distance between nNOS and the sarcolemma may impair NO diffusion
through the myocyte membrane to the microvasculature. As a consequence, insufficient NO
release follows muscle contraction resulting in muscle ischemia23. Unopposed
vasoconstriction may, therefore, explain the necrosis observed in skeletal and cardiac muscle
of dystrophinopathy patients. Microvasculature abnormalities have also been shown to result
primarily from absence of dystrophin or sarcoglycan components of the DGC in
cardiomyocytes24, 25.
X inactivation, the random process by which one of the two X chromosomes in female cells
becomes transcriptionally inactive, may result in cardiomyocytes with an active X-
chromosome with the abnormal dystrophin gene. The X-chromosome containing the normal
dystrophin gene may become inactivated in cardiac muscle to a greater degree than in
skeletal muscle, causing female carriers to develop dystrophinopathic cardiomyopathy. The
exact prevalence and severity of such in the carrier population is uncertain26–29.
I.2 Cardiac Disease and Imaging Phenotype
Almost all DMD patients who survive to the third decade of life display cardiomyopathy30.
Recognition may be delayed by relative physical inactivity obscuring symptomatology. This
most common and severe form of childhood muscular dystrophies is associated with
increased R/S ratio in the right precordial ECG leads, deep Q waves in the lateral leads,
conduction abnormalities and arrhythmias (mainly supraventricular but also ventricular).
BMD patients, whose skeletal myopathy occurs later and progresses more slowly,
experience worse cardiomyopathy than DMD patients: up to 70% have LV dysfunction by
echocardiography. Perhaps because of less skeletal muscle weakness, these patients can
perform more strenuous exercise with dystrophin-deficient myocardial muscle fibers and
have earlier manifestations of myocardial disease31.
Most CMR data in muscular dystrophies currently exists for patients with DMD and BMD.
The pathology of cardiomyopathy in patients with dystrophinopathy classically produces
subepicardial fibrosis of the inferolateral wall32, remarkably similar to the pattern observed
in some patients with viral myocarditis (Figs. 2–3, Movie Files 1–2). Myocardial damage in
DMD/BMD has been postulated to result from mechanical stress imposed on a
metabolically and structurally abnormal myocardium, although it remains unclear how a
genetic abnormality presumably affecting the heart in a diffuse manner may result in a
segmental distribution. Whether the inferolateral wall is more vulnerable due to regional
molecular changes caused by the mutation or if this regional susceptibility results from
exposure to higher mechanical stress remains to be elucidated10. Of note, enterovirus
infection has been shown to produce myocardial damage via cleavage of dystrophin33; this
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mechanism may help explain the similarity in LGE pattern between myocarditis and
dystrophin-associated cardiomyopathy.
The rationale to perform CMR in BMD/DMD patients in addition to the current standard of
care (monitoring by echocardiography and ECG) is based on 2 sets of observations. First,
studies have shown that early initiation of standard heart failure therapy can delay the onset
and progression of left ventricular systolic dysfunction and potentially even lead to reverse
remodeling in patients with X-linked dystrophinopathy2–6. Second, it has been shown that
myocardial fibrosis detected by late gadolinium-enhancement imaging may be observed
even when findings by echocardiography are still normal9, 10 (Fig. 2). CMR can therefore
serve as a more sensitive means to detect early cardiac involvement and help to decide when
cardioprotective treatment should be instituted. In addition to late gadolinium-enhancement,
CMR also provides accurate and reproducible quantification of LV volumes, making this
modality well suited for monitoring response to both standard therapy and novel treatment
strategies.
Cardiac screening has been recommended for female DMD/BMD mutation carriers,
particularly beginning after the teenage years as they are known to be at risk for developing
cardiomyopathy28. Interestingly, CMR has revealed a similar pattern of myocardial fibrosis
in mutation carriers as that seen in DMD patients (Fig. 4)34. Since myocardial damage in
carriers has been observed even in absence of clinically-apparent muscular weakness,
cardiac screening should be considered in female relatives of DMD/BMD patients.
II. Emery-Dreifuss Muscular Dystrophies
II.1 Clinical and Genetic Features
The nuclear envelope is composed of a double lipid bilayer that separates the contents of the
nucleus from the cytoplasm. Within the inner nuclear membrane are a variety of integral
proteins. Emery-Dreifuss muscular dystrophy (EDMD) is a form of muscular dystrophy
caused by mutations in these nuclear membrane proteins. One of these proteins, emerin,
(Fig. 1) is almost completely absent in the X-linked form of EDMD due to a mutation in the
EMD gene35. The exact function of emerin is not clear; it binds to a variety of other nuclear
factors involved in gene regulation, mRNA splicing, ordering of chromatin structure and
nuclear assembly36. EDMD can also occur as an autosomal dominant (AD) or recessive
(AR) disorder resulting from mutations in the LMNA gene that encodes lamins A and C37.
Lamins A and C are nuclear intermediate-filament proteins which closely interact with
emerin and other nuclear membrane proteins, thereby forming aproteinaceous meshwork
(the nuclear lamina) that underlies the inner nuclear membrane (Fig. 1). This meshwork has
an important role inmaintaining the architecture and mechanical strengthof the nucleus; it
also serves as a scaffold for various other nuclear factors involved in DNA replication,
chromatin organization and transcription38–41. Deficiency in either emerin or lamin A/C
typically results in the triad of contractures, muscle weakening and cardiac conduction
defects by mechanisms that remain elusive.
Cardiac involvement in EDMD patients is common and usually becomes evident in the third
decade as muscle weakness progresses8, though cardiac manifestations have also been
reported in young adults without muscle weakness. Since cardiac dysfunction portends a
high risk of sudden death42, careful follow-up of these patients is mandatory. In EDMD,
normal myocardium is gradually replaced by fibrous and adipose tissue, a process that
usually starts in the atria (leading to atrial arrhythmias), often involves the atrioventricular
node (leading to conduction abnormalities sometimes requiring pacemaker implantation)
and eventually affects the ventricles (causing progressive dilatation and systolic failure)43,
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44. Because sudden death may be the presenting symptom in this disease, cardiac screening
of relatives (including female carriers with X-linked EDMD) has been recommended7, 44.
II.2 Cardiac Magnetic Resonance Imaging Phenotype
In EDMD, CMR data are limited due to the rarity of the disease but also because of the
frequent need for pacemaker implantation in this population (particularly in the more
advanced stages of the disease). A study by Smith et al.45 in 8 patients with the AD subtype
of EDMD (EDMD2; LMNA gene mutation at 1q21) showed that early stage disease does
not display apparent fibrosis, despite the presence of more subtle myocardial abnormalities
including a decrease in systolic circumferential strain in the inferior segment. This suggests
a different pathogenesis of cardiac involvement in EDMD compared to DMD/BMD, where
fibrosis typically precedes systolic dysfunction.
III. Limb Girdle Muscular Dystrophies
III.1 Clinical and Genetic Features
Limb-girdle muscular dystrophy (LGMD) refers to a group of disorders with great clinical
and genetic heterogeneity, all characterized by weakness affecting the proximal
musculature. AD and AR inheritance patterns have been identified. The more common AR
subtypes usually have an earlier age of onset, and show more rapid disease progression
compared to AD variants. The subtypes mostly associated with cardiac involvement
(manifest as conduction disorders and/or myocardial disease) are those associated with a
defect in the genes encoding for the α-(LGMD2D), β-(LGMD2E), γ-(LGMD2C) or δ-
(LGMD2F) subunits of the dystrophin-associated sarcoglycan complex in heart and skeletal
muscle (Fig. 1)46. Cardiomyopathy is also very common in LGMD2I, caused by a mutation
in fukutin-related protein (FKRP). FKRP is an enzyme involved in the glycosylation of α-
dystroglycan, a peripheral membrane component of the dystrophin-associated glycoprotein
complex. Post-translational glycosylation by FRKP allows α-dystroglycan to bind with the
extracellular matrix, making it an important component in the link among cytoskeleton,
sarcolemmal dystrophin-associated glycoprotein complex and extracellular matrix.
The AD subtype LGMD1B is also caused by a defect in the LMNA gene encoding for lamin
A/C, resulting in a phenotype similar to autosomal dominant EDMD but with a different
distribution of muscle involvement. The pelvic girdle weakness in LGMD1B is slowly
progressive, sparing the lower muscles. Additionally, contractures and cardiac disease
manifestations (atrioventricular block, sudden death, atrial paralysis, atrial fibrillation/flutter
and dilated cardiomyopathy) tend to occur later compared to autosomal dominant EDMD47,
48.
Different mutations involving the LMNA gene have been described, resulting in a clinically
heterogeneous group of disorders (laminopathies) spanning muscular dystrophy, progeria,
familial partial lipodystrophy and Charcot-Marie-Tooth disease. The muscular dystrophies
associated with LMNA gene mutation that cause cardiac disease include the autosomal
variants of EDMD, LGMD1B, and a third disorder commonly referred to as dilated
cardiomyopathy with conductive system disease. The last, although initially linked to
chromosome 1p1-1q149 was later associated with mutations in the lamin A/C gene (1p1-q21
locus)50. Patients with this defect develop sinus node dysfunction, atrioventricular node
dysfunction, ventricular arrhythmias and adult-onset cardiomyopathy with little clinical
evidence of skeletal myopathy. The inheritance pattern is autosomal dominant with high
penetrance, and patients have a high risk of sudden death50.
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III.2 Cardiac Imaging Phenotype
In lamin A/C cardiomyopathy, we have demonstrated midmyocardial scarring of the basal
interventricular septum by LGE that occurs well before the onset of ventricular dilatation
and systolic dysfunction (Fig. 4), and which may herald conduction system disease51. This
midwall fibrosis is similar in distribution to that observed at autopsy, and in our experience
is often associated with diastolic dysfunction. Further studies are needed to define the
prognostic significance of midwall fibrosis in this population, as it may represent substrate
for potentially fatal ventricular arrhythmias seen in these patients as reported in other
cardiomyopathies52–54. While skeletal muscle disease may not be readily apparent
clinically, we have detected clear alterations involving the medial head of the gastronemius
muscles by magnetic resonance imaging (Fig. 5), similar to that described in patients with
EDMD255. This suggests the presence of a continuum between phenotypes with
predominant cardiac involvement and phenotypes with cardiac and skeletal muscle
compromise56.
IV. Myotonic Dystrophy
IV.1 Clinical and Genetic Features
Myotonic dystrophy (DM) is an autosomal dominant muscular dystrophy that produces
progressive skeletal muscle wasting and cardiac conduction abnormalities; multisystem
manifestations include cataracts, testicular failure, hypogammaglobulinemia and insulin
resistance. As shown in the Table, two types of DM have been identified. DM1 is the most
common form and is associated with an abnormal expansion of a CTG-trinucleotide repeat
sequence in the DMPK gene that codes for myotonic dystrophy protein kinase, a protein
mainly expressed in smooth, cardiac and skeletal muscle cells. Disease severity and age of
onset in DM1 correlates with CTG expansion length, and the number of repeats can increase
from one generation to the next (anticipation). DM2 on the other hand is associated with an
expanded CCTG-tetranucleotide repeat in a totally unrelated gene, coding for zinc finger
protein. In both cases, the gene including the abnormal repeat sequences is transcribed into
RNA but not translated. The mutant RNA accumulates in the nucleus57 and disturbs the
function of RNA-binding proteins that normally participate in splicing of pre-messenger
RNA into mature mRNA. This eventually results in abnormal function of different genes,
including those encoding for the muscle-specific chloride channel ClC-1 and insulin
receptor, at least partially explaining the features of myotonia and insulin resistance in
patients with DM58.
Atrioventricular and intraventricular conduction defects are common in both DM1 and
DM2. Infra-hisian block is likely an important cause of sudden death in these patients59, 60.
As in many other types of muscular dystrophy, cardiac arrhythmias may occur early in the
disease course i.e. in the absence of severe neuromuscular impairment. Structural heart
disease is also frequently observed in DM, with LV dilatation or hypertrophy observed in
approximately 20% of patients, and LV systolic dysfunction in 14%61. Clinical heart failure,
however, is less common—2% according to that same report.
IV.2 Cardiac Imaging Phenotype
Gaul et al. recently described the CMR findings in 9 patients with LGMD2I (due to a
mutation in the FKRP gene)62. They found CMR to be more sensitive than conventional
diagnostic investigations (ECG and echocardiography) for detecting cardiac involvement,
which was manifest as a decrease in ejection fraction and/or an increase in LV volumes and
mass. Unfortunately, no results from late gadolinium-enhancement imaging were reported in
that study. Our own experience with CMR in patients with LGMD2I suggests that at an
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early stage, when LV size and function are still normal, midmyocardial scarring may be
observed. As cardiomyopathy advances, extensive myocardial fibrosis is apparent (Fig. 6).
A similar pattern of fibrosis was recently reported by Yilmaz et al. in a patient with
LGMD2C63. Taken together, these findings suggest that different abnormalities within the
dystrophin-sarcoglycan-dystroglycan complex may all lead to cardiomyocyte instability and
damage, eventually resulting in a characteristic (but non-specific) pattern of fibrosis.
Patients with DM may present with cardiomyopathy, which usually is more benign in DM2
compared to DM1. CMR may help define the LV abnormalities of the disease: dilatation,
systolic dysfunction, hypertrophy, and occasionally non-compaction64, 65. Typical LGE
patterns have not been reported in DM. In our experience, mild midwall fibrosis involving
the septum is occasionally present; the clinical significance of this finding in DM remains
uncertain.
V. Beyond LGE
V.1 Myocardial Strain Analysis
The assumption that cardiac dysfunction can be prevented (or at least be attenuated) in
patients with MD has led to the belief that therapy should be initiated at an early stage of the
disease, rather than delayed until ventricular dilatation or systolic dysfunction become
apparent. CMR has been proposed as a sensitive screening tool for that purpose by its ability
to show myocardial fibrosis, even when the LV is otherwise structurally normal. Another
means of revealing occult cardiac dysfunction in patients with MD may be provided by
strain analysis. Ashford et al. used CMR tagging to show that boys with DMD exhibit
abnormal global and segmental circumferential strain compared to age- and gender-matched
controls, despite similar LV volumes and ejection fraction66. Similar findings were recently
reported by Hor et al., who showed abnormalities in myocardial strain preceded both the
age-dependent decline in ejection fraction and the appearance of myocardial fibrosis in
DMD patients67. This group recently showed that strain analysis better captures serial
decline in LV function compared to EF68. The sensitivity of strain imaging analysis by
CMR could potentially be used not only to reveal occult cardiac dysfunction, but also to
assess the efficacy of existing or novel therapeutic agents. Some questions remain, however,
regarding these tools, particularly in terms of their accuracy for measuring strain on a
segmental (rather than global) level, but also with respect to the reproducibility of strain
measurements among centers. Prospective and multicenter studies that randomize patients to
therapeutic decision making with or without strain imaging analysis are therefore critically
needed before these new techniques can become adopted into the clinical management of
patients with muscular dystrophy69.
V.2 Fat vs. Water Imaging
Histological studies of autopsy hearts from DMD patients suggest a component of fat
infiltration, described as “predominantly epimyocardial” in a small case series32. CMR may
distinguish fat using either cine or LGE imaging techniques that take advantage of the
consistent difference in resonant frequency of water vs. fat protons70. Studying 3 DMD dogs
with these techniques, Kellman et al. demonstrated that extensive epicardial
hyperenhacement on LGE imaging that at least in part was attributable to fat71. Our
experience in one patient with early myocardial disease using the same technique suggests
that LGE in patients with dystrophin-associated cardiomyopathy may also demonstrate a
component of fatty infiltration (Fig. 7, Movie File 3). T2-weighted CMR, which depicts
myocardial water’s distribution, may provide additional insights into the myocardial disease
of DMD72.
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VI. Suggested CMR Protocol and Clinical Implications of Findings
VI.1 Suggested CMR Protocol
When designing a CMR examination for the patient with muscular dystrophy, the key
clinical questions should be addressed: What is the degree of LV dysfunction? What
evidence is there for myocardial disease? What pattern of disease is present? What is the
likelihood of functional recovery? Acquisitions should include cine imaging in all standard
long axis and contiguous short axis planes; real-time cine techniques may be necessary in
patients who have difficulty breathholding. Fat-suppressed or fat-only cine imaging if
available may help delineate the extent of myocardial fat infiltration. Finally, LGE
acquisition forms the cornerstone of any CMR protocol in patients with cardiomyopathy,
and the same is true in evaluating the MD patient. While the optimal contrast dose and
acquisition timing have not been specifically interrogated in MD cardiomyopathy LGE
imaging, our experience suggests that values similar to those used for other nonischemic
cardiomyopathies (save amyloidosis) perform well. If fat and water can be distinctly imaged
with specialized LGE sequences, these may shed further insight into the extent of fibrosis
vs. fatty infiltration of the myocardium. While absence of hyperenhancement has established
value in predicting response to, for instance, medical and resynchronization therapies in
other cardiomyopathy populations, the predictive value in MD-associated myocardial
disease remains to be established. Given evidence that subclinical abnormalities in regional
strain may precede overt contractile dysfunction, strain analysis may be included at centers
where robust postprocessing affords reproducible results.
VI.2 Clinical Implications of Findings
Increased recognition of subclinical myocardial changes with advanced imaging raises
challenging management questions. Evidence-based guidelines for patients with
cardiomyopathy advocate initiation of drugs like angiotensin converting enzyme inhibitors
(ACEI) and beta-blockers in stage B cardiomyopathy, defined in the adult guidelines as
“impaired left ventricular (LV) function, hypertrophy, or geometric chamber distortion”73.
Pediatric guidelines also advocate ACEI therapy for subclinical LV dysfunction74; notably,
neither document addresses management of myocardial fibrosis that may be present in the
absence of structural and functional changes. Our approach is to initiate ACEI and
occasionally aldosterone antagonist therapy, given the proven antifibrotic effect of both in
other cardiomyopathy populations75, if CMR demonstrates myocardial fibrosis in the
muscular dystrophy patient and particularly in the lamin A/C mutation-positive patient.
While one prospective, randomized trial in children with DMD supports a possible long-
term benefit with ACEI even if the initial LV ejection fraction by echocardiography is
normal76, it is unknown if any of these patients had subclinical fibrosis in the absence of
CMR data. A strategy of fibrosis-guided initiation of cardioprotective drug therapy requires
prospective, randomized trial data before it can be widely advocated.
Electrophysiological testing should be considered in muscular dystrophy-associated
cardiomyopathies known to affect conduction system such as DM and lamin A/C. Timing of
such may be informed by symptoms suspicious for conduction system disease or conduction
abnormalities by electrocardiography77. We have observed longer PR intervals in lamin A/C
patients with septal fibrosis by CMR relative to those of mutation-positive patients without
evident fibrosis51; longitudinal studies are suggested to test the predictive value of
hyperenhancement for pacemaker requirement in appropriate DM and lamin A/C patients.
VII. Cardiac Disease in MD: Genotype vs. Phenotype
One of the major problems for clinicians dealing with the cardiovascular complications of
MD is that clear correlations between genotype and phenotype have been difficult to
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achieve. It remains unclear why distinct mutations may result in a clinically
indistinguishable phenotype, while strikingly different phenotypes may result in carriers of
identical gene mutations or even among affected siblings. In this respect, MD-associated
cardiomyopathies are no different from other heritable cardiomyopathies (hypertrophic
cardiomyopathy, for instance). Although there is little doubt that genotype plays a central
role in initiating the cardiomyopathic process, the ultimate cardiovascular phenotype is
likely also determined by multiple other interacting factors, including genetic background
effects, biomechanical stress pathways (with loss of functional myocardium creating
additional stress on remaining viable heart muscle) and modifying effects of calcium cycling
and signaling78, 79.
A better understanding of clinical variability in MD-associated myocardial disease will,
therefore, require identification of modifying genes and improved knowledge of gene-
protein function and protein interactions. Importantly, it will also benefit from continued
advances in cardiac phenotyping; lack of sensitivity in the armamentarium of diagnostic
tests has previously impaired detection of early cardiac involvement in many of these
patients. The greater sensitivity and reproducibility of CMR to demonstrate early
abnormalities or subtle changes in serial assessment offers the promise of better defining the
natural history, and offers significant value in developing novel therapeutic approaches for
these disorders. It is hoped that this review’s demonstration of limitations of current state-of-
the-art in imaging phenotype prompts synergistic efforts among geneticists, molecular
biologists and CMR specialists to eventually generate new insights into the pathogenesis and
expression of cardiac disease in muscular dystrophy, which is critically needed to help
reduce the burden of heart disease in this patient population.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
Acknowledgments




1. Bach JR. Update and perspective on noninvasive respiratory muscle aids. Part 2: The expiratory
aids. Chest 1994;105:1538–1544. [PubMed: 8181348]
2. Duboc D, Meune C, Lerebours G, Devaux JY, Vaksmann G, Becane HM. Effect of perindopril on
the onset and progression of left ventricular dysfunction in Duchenne muscular dystrophy. J Am
Coll Cardiol 2005;45:855–857. [PubMed: 15766818]
3. Ishikawa Y, Bach JR, Minami R. Cardioprotection for Duchenne’s muscular dystrophy. Am Heart J
1999;137:895–902. [PubMed: 10220639]
4. Jefferies JL, Eidem BW, Belmont JW, Craigen WJ, Ware SM, Fernbach SD, Neish SR, Smith EO,
Towbin JA. Genetic predictors and remodeling of dilated cardiomyopathy in muscular dystrophy.
Circulation 2005;112:2799–2804. [PubMed: 16246949]
5. Kajimoto H, Ishigaki K, Okumura K, Tomimatsu H, Nakazawa M, Saito K, Osawa M, Nakanishi T.
Beta-blocker therapy for cardiac dysfunction in patients with muscular dystrophy. Circ J
2006;70:991–994. [PubMed: 16864930]
Verhaert et al. Page 8













6. Ramaciotti C, Heistein LC, Coursey M, Lemler MS, Eapen RS, Iannaccone ST, Scott WA. Left
ventricular function and response to enalapril in patients with duchenne muscular dystrophy during
the second decade of life. Am J Cardiol 2006;98:825–827. [PubMed: 16950195]
7. Bouhouch R, Elhouari T, Oukerraj L, Fellat I, Zarzur J, Bennani R, Arharbi M. Management of
cardiac involvement in neuromuscular diseases: review. Open Cardiovasc Med J 2008;2:93–96.
[PubMed: 19337361]
8. Emery AE. The muscular dystrophies. Lancet 2002;359:687–695. [PubMed: 11879882]
9. Silva MC, Meira ZM, Gurgel Giannetti J, da Silva MM, Campos AF, Barbosa Mde M, Starling
Filho GM, Ferreira Rde A, Zatz M, Rochitte CE. Myocardial delayed enhancement by magnetic
resonance imaging in patients with muscular dystrophy. J Am Coll Cardiol 2007;49:1874–1879.
[PubMed: 17481447]
10. Yilmaz A, Gdynia HJ, Baccouche H, Mahrholdt H, Meinhardt G, Basso C, Thiene G, Sperfeld AD,
Ludolph AC, Sechtem U. Cardiac involvement in patients with Becker muscular dystrophy: new
diagnostic and pathophysiological insights by a CMR approach. J Cardiovasc Magn Reson
2008;10:50. [PubMed: 18983659]
11. Hoffman EP, Brown RH Jr, Kunkel LM. Dystrophin: the protein product of the Duchenne
muscular dystrophy locus. Cell 1987;51:919–928. [PubMed: 3319190]
12. Monaco AP, Bertelson CJ, Liechti-Gallati S, Moser H, Kunkel LM. An explanation for the
phenotypic differences between patients bearing partial deletions of the DMD locus. Genomics
1988;2:90–95. [PubMed: 3384440]
13. Rafael JA, Cox GA, Corrado K, Jung D, Campbell KP, Chamberlain JS. Forced expression of
dystrophin deletion constructs reveals structure-function correlations. J Cell Biol 1996;134:93–
102. [PubMed: 8698825]
14. Corrado K, Rafael JA, Mills PL, Cole NM, Faulkner JA, Wang K, Chamberlain JS. Transgenic
mdx mice expressing dystrophin with a deletion in the actin-binding domain display a “mild
Becker” phenotype. J Cell Biol 1996;134:873–884. [PubMed: 8769413]
15. Kaspar RW, Allen HD, Ray WC, Alvarez CE, Kissel JT, Pestronk A, Weiss RB, Flanigan KM,
Mendell JR, Montanaro F. Analysis of dystrophin deletion mutations predicts age of
cardiomyopathy onset in becker muscular dystrophy. Circ Cardiovasc Genet 2009;2:544–551.
[PubMed: 20031633]
16. Feng J, Yan JY, Buzin CH, Sommer SS, Towbin JA. Comprehensive mutation scanning of the
dystrophin gene in patients with nonsyndromic X-linked dilated cardiomyopathy. J Am Coll
Cardiol 2002;40:1120–1124. [PubMed: 12354438]
17. Menke A, Jockusch H. Extent of shock-induced membrane leakage in human and mouse myotubes
depends on dystrophin. J Cell Sci 1995;108:727–733. [PubMed: 7769014]
18. Pasternak C, Wong S, Elson EL. Mechanical function of dystrophin in muscle cells. J Cell Biol
1995;128:355–361. [PubMed: 7844149]
19. Franco-Obregon A Jr, Lansman JB. Mechanosensitive ion channels in skeletal muscle from normal
and dystrophic mice. J Physiol 1994;481:299–309. [PubMed: 7537813]
20. Fong PY, Turner PR, Denetclaw WF, Steinhardt RA. Increased activity of calcium leak channels in
myotubes of Duchenne human and mdx mouse origin. Science 1990;250:673–676. [PubMed:
2173137]
21. Jung C, Martins AS, Niggli E, Shirokova N. Dystrophic cardiomyopathy: amplification of cellular
damage by Ca2+ signalling and reactive oxygen species-generating pathways. Cardiovasc Res
2008;77:766–773. [PubMed: 18056762]
22. Bia BL, Cassidy PJ, Young ME, Rafael JA, Leighton B, Davies KE, Radda GK, Clarke K.
Decreased myocardial nNOS, increased iNOS and abnormal ECGs in mouse models of Duchenne
muscular dystrophy. J Mol Cell Cardiol 1999;31:1857–1862. [PubMed: 10525423]
23. Sander M, Chavoshan B, Harris SA, Iannaccone ST, Stull JT, Thomas GD, Victor RG. Functional
muscle ischemia in neuronal nitric oxide synthase-deficient skeletal muscle of children with
Duchenne muscular dystrophy. Proc Natl Acad Sci U S A 2000;97:13818–13823. [PubMed:
11087833]
Verhaert et al. Page 9













24. Wheeler MT, Allikian MJ, Heydemann A, Hadhazy M, Zarnegar S, McNally EM. Smooth muscle
cell-extrinsic vascular spasm arises from cardiomyocyte degeneration in sarcoglycan-deficient
cardiomyopathy. J Clin Invest 2004;113:668–675. [PubMed: 14991064]
25. Hainsey TA, Senapati S, Kuhn DE, Rafael JA. Cardiomyopathic features associated with muscular
dystrophy are independent of dystrophin absence in cardiovasculature. Neuromuscul Disord
2003;13:294–302. [PubMed: 12868498]
26. Grain L, Cortina-Borja M, Forfar C, Hilton-Jones D, Hopkin J, Burch M. Cardiac abnormalities
and skeletal muscle weakness in carriers of Duchenne and Becker muscular dystrophies and
controls. Neuromuscul Disord 2001;11:186–191. [PubMed: 11257476]
27. Hoogerwaard EM, van der Wouw PA, Wilde AA, Bakker E, Ippel PF, Oosterwijk JC, Majoor-
Krakauer DF, van Essen AJ, Leschot NJ, de Visser M. Cardiac involvement in carriers of
Duchenne and Becker muscular dystrophy. Neuromuscul Disord 1999;9:347–351. [PubMed:
10407858]
28. Nolan MA, Jones OD, Pedersen RL, Johnston HM. Cardiac assessment in childhood carriers of
Duchenne and Becker muscular dystrophies. Neuromuscul Disord 2003;13:129–132. [PubMed:
12565910]
29. Politano L, Nigro V, Nigro G, Petretta VR, Passamano L, Papparella S, Di Somma S, Comi LI.
Development of cardiomyopathy in female carriers of Duchenne and Becker muscular dystrophies.
JAMA 1996;275:1335–1338. [PubMed: 8614119]
30. McNally EM. New approaches in the therapy of cardiomyopathy in muscular dystrophy. Annu Rev
Med 2007;58:75–88. [PubMed: 17217326]
31. Melacini P, Fanin M, Danieli GA, Villanova C, Martinello F, Miorin M, Freda MP, Miorelli M,
Mostacciuolo ML, Fasoli G, Angelini C, Dalla Volta S. Myocardial involvement is very frequent
among patients affected with subclinical Becker’s muscular dystrophy. Circulation 1996;94:3168–
3175. [PubMed: 8989125]
32. Frankel KA, Rosser RJ. The pathology of the heart in progressive muscular dystrophy:
epimyocardial fibrosis. Hum Pathol 1976;7:375–386. [PubMed: 939536]
33. Badorff C, Knowlton KU. Dystrophin disruption in enterovirus-induced myocarditis and dilated
cardiomyopathy: from bench to bedside. Med Microbiol Immunol 2004;193:121–126. [PubMed:
12920582]
34. Yilmaz A, Gdynia HJ, Ludolph AC, Klingel K, Kandolf R, Sechtem U. Images in cardiovascular
medicine. Cardiomyopathy in a Duchenne muscular dystrophy carrier and her diseased son:
similar pattern revealed by cardiovascular MRI. Circulation 2010;121:e237–239. [PubMed:
20231539]
35. Bione S, Maestrini E, Rivella S, Mancini M, Regis S, Romeo G, Toniolo D. Identification of a
novel X-linked gene responsible for Emery-Dreifuss muscular dystrophy. Nat Genet 1994;8:323–
327. [PubMed: 7894480]
36. Bengtsson L, Wilson KL. Multiple and surprising new functions for emerin, a nuclear membrane
protein. Curr Opin Cell Biol 2004;16:73–79. [PubMed: 15037308]
37. Bonne G, Di Barletta MR, Varnous S, Becane HM, Hammouda EH, Merlini L, Muntoni F,
Greenberg CR, Gary F, Urtizberea JA, Duboc D, Fardeau M, Toniolo D, Schwartz K. Mutations in
the gene encoding lamin A/C cause autosomal dominant Emery-Dreifuss muscular dystrophy. Nat
Genet 1999;21:285–288. [PubMed: 10080180]
38. Burke B, Stewart CL. Life at the edge: the nuclear envelope and human disease. Nat Rev Mol Cell
Biol 2002;3:575–585. [PubMed: 12154369]
39. Gruenbaum Y, Margalit A, Goldman RD, Shumaker DK, Wilson KL. The nuclear lamina comes of
age. Nat Rev Mol Cell Biol 2005;6:21–31. [PubMed: 15688064]
40. Holaska JM. Emerin and the nuclear lamina in muscle and cardiac disease. Circ Res 2008;103:16–
23. [PubMed: 18596264]
41. Mounkes L, Kozlov S, Burke B, Stewart CL. The laminopathies: nuclear structure meets disease.
Curr Opin Genet Dev 2003;13:223–230. [PubMed: 12787783]
42. Sakata K, Shimizu M, Ino H, Yamaguchi M, Terai H, Fujino N, Hayashi K, Kaneda T, Inoue M,
Oda Y, Fujita T, Kaku B, Kanaya H, Mabuchi H. High incidence of sudden cardiac death with
Verhaert et al. Page 10













conduction disturbances and atrial cardiomyopathy caused by a nonsense mutation in the STA
gene. Circulation 2005;111:3352–3358. [PubMed: 15967842]
43. Buckley AE, Dean J, Mahy IR. Cardiac involvement in Emery Dreifuss muscular dystrophy: a case
series. Heart 1999;82:105–108. [PubMed: 10377322]
44. Fishbein MC, Siegel RJ, Thompson CE, Hopkins LC. Sudden death of a carrier of X-linked
Emery-Dreifuss muscular dystrophy. Ann Intern Med 1993;119:900–905. [PubMed: 8215002]
45. Smith GC, Kinali M, Prasad SK, Bonne G, Muntoni F, Pennell DJ, Nihoyannopoulos P. Primary
myocardial dysfunction in autosomal dominant EDMD. A tissue doppler and cardiovascular
magnetic resonance study. J Cardiovasc Magn Reson 2006;8:723–730. [PubMed: 16891232]
46. Norwood F, de Visser M, Eymard B, Lochmuller H, Bushby K. EFNS guideline on diagnosis and
management of limb girdle muscular dystrophies. Eur J Neurol 2007;14:1305–1312. [PubMed:
18028188]
47. Kitaguchi T, Matsubara S, Sato M, Miyamoto K, Hirai S, Schwartz K, Bonne G. A missense
mutation in the exon 8 of lamin A/C gene in a Japanese case of autosomal dominant limb-girdle
muscular dystrophy and cardiac conduction block. Neuromuscul Disord 2001;11:542–546.
[PubMed: 11525883]
48. Muchir A, Bonne G, van der Kooi AJ, van Meegen M, Baas F, Bolhuis PA, de Visser M, Schwartz
K. Identification of mutations in the gene encoding lamins A/C in autosomal dominant limb girdle
muscular dystrophy with atrioventricular conduction disturbances (LGMD1B). Hum Mol Genet
2000;9:1453–1459. [PubMed: 10814726]
49. Kass S, MacRae C, Graber HL, Sparks EA, McNamara D, Boudoulas H, Basson CT, Baker PB
3rd, Cody RJ, Fishman MC, Cox N, Kong A, Wooley CF, Seidman JG, Seidman CE. A gene
defect that causes conduction system disease and dilated cardiomyopathy maps to chromosome
1p1-1q1. Nat Genet 1994;7:546–551. [PubMed: 7951328]
50. Fatkin D, MacRae C, Sasaki T, Wolff MR, Porcu M, Frenneaux M, Atherton J, Vidaillet HJ Jr,
Spudich S, De Girolami U, Seidman JG, Seidman C, Muntoni F, Muehle G, Johnson W,
McDonough B. Missense mutations in the rod domain of the lamin A/C gene as causes of dilated
cardiomyopathy and conduction-system disease. N Engl J Med 1999;341:1715–1724. [PubMed:
10580070]
51. Raman SV, Sparks EA, Baker PM, McCarthy B, Wooley CF. Mid-myocardial fibrosis by cardiac
magnetic resonance in patients with lamin A/C cardiomyopathy: possible substrate for diastolic
dysfunction. J Cardiovasc Magn Reson 2007;9:907–913. [PubMed: 18066751]
52. Assomull RG, Prasad SK, Lyne J, Smith G, Burman ED, Khan M, Sheppard MN, Poole-Wilson
PA, Pennell DJ. Cardiovascular magnetic resonance, fibrosis, and prognosis in dilated
cardiomyopathy. J Am Coll Cardiol 2006;48:1977–1985. [PubMed: 17112987]
53. Hsia HH, Marchlinski FE. Characterization of the electroanatomic substrate for monomorphic
ventricular tachycardia in patients with nonischemic cardiomyopathy. Pacing Clin Electrophysiol
2002;25:1114–1127. [PubMed: 12164454]
54. Nazarian S, Bluemke DA, Lardo AC, Zviman MM, Watkins SP, Dickfeld TL, Meininger GR,
Roguin A, Calkins H, Tomaselli GF, Weiss RG, Berger RD, Lima JA, Halperin HR. Magnetic
resonance assessment of the substrate for inducible ventricular tachycardia in nonischemic
cardiomyopathy. Circulation 2005;112:2821–2825. [PubMed: 16267255]
55. Mercuri E, Counsell S, Allsop J, Jungbluth H, Kinali M, Bonne G, Schwartz K, Bydder G,
Dubowitz V, Muntoni F. Selective muscle involvement on magnetic resonance imaging in
autosomal dominant Emery-Dreifuss muscular dystrophy. Neuropediatrics 2002;33:10–14.
[PubMed: 11930270]
56. Carboni N, Mura M, Marrosu G, Cocco E, Marini S, Solla E, Mateddu A, Maioli MA, Piras R,
Mallarini G, Mercuro G, Porcu M, Marrosu MG. Muscle imaging analogies in a cohort of patients
with different clinical phenotypes caused by LMNA gene mutations. Muscle Nerve 2010;41:458–
463. [PubMed: 19882644]
57. Cooper TA. A reversal of misfortune for myotonic dystrophy? N Engl J Med 2006;355:1825–
1827. [PubMed: 17065646]
58. Ranum LP, Cooper TA. RNA-mediated neuromuscular disorders. Annu Rev Neurosci
2006;29:259–277. [PubMed: 16776586]
Verhaert et al. Page 11













59. Babuty D, Fauchier L, Tena-Carbi D, Poret P, Leche J, Raynaud M, Fauchier JP, Cosnay P. Is it
possible to identify infrahissian cardiac conduction abnormalities in myotonic dystrophy by non-
invasive methods? Heart 1999;82:634–637. [PubMed: 10525524]
60. Melacini P, Buja G, Fasoli G, Angelini C, Armani M, Scognamiglio R, Dalla Volta S. The natural
history of cardiac involvement in myotonic dystrophy: an eight-year follow-up in 17 patients. Clin
Cardiol 1988;11:231–238. [PubMed: 3365873]
61. Bhakta D, Lowe MR, Groh WJ. Prevalence of structural cardiac abnormalities in patients with
myotonic dystrophy type I. Am Heart J 2004;147:224–227. [PubMed: 14760317]
62. Gaul C, Deschauer M, Tempelmann C, Vielhaber S, Klein HU, Heinze HJ, Zierz S, Grothues F.
Cardiac involvement in limb-girdle muscular dystrophy 2I: conventional cardiac diagnostic and
cardiovascular magnetic resonance. J Neurol 2006;253:1317–1322. [PubMed: 16786213]
63. Yilmaz A, Suttie J, Petersen SE. Letter regarding article, “analysis of dystrophin deletion
mutations predicts age of cardiomyopathy onset in Becker muscular dystrophy”. Circ Cardiovasc
Genet 2010;3:e1. author reply e2. [PubMed: 20407095]
64. Finsterer J, Stolberger C, Kopsa W. Noncompaction in myotonic dystrophy type 1 on cardiac MRI.
Cardiology 2005;103:167–168. [PubMed: 15785023]
65. Wahbi K, Meune C, Bassez G, Laforet P, Vignaux O, Marmursztejn J, Becane HM, Eymard B,
Duboc D. Left ventricular non-compaction in a patient with myotonic dystrophy type 2.
Neuromuscul Disord 2008;18:331–333. [PubMed: 18395448]
66. Ashford MW Jr, Liu W, Lin SJ, Abraszewski P, Caruthers SD, Connolly AM, Yu X, Wickline SA.
Occult cardiac contractile dysfunction in dystrophin-deficient children revealed by cardiac
magnetic resonance strain imaging. Circulation 2005;112:2462–2467. [PubMed: 16216964]
67. Hor KN, Wansapura J, Markham LW, Mazur W, Cripe LH, Fleck R, Benson DW, Gottliebson
WM. Circumferential strain analysis identifies strata of cardiomyopathy in Duchenne muscular
dystrophy: a cardiac magnetic resonance tagging study. J Am Coll Cardiol 2009;53:1204–1210.
[PubMed: 19341862]
68. Hagenbuch SC, Gottliebson WM, Wansapura J, Mazur W, Fleck R, Benson DW, Hor KN.
Detection of progressive cardiac dysfunction by serial evaluation of circumferential strain in
patients with Duchenne muscular dystrophy. Am J Cardiol 2010;105:1451–1455. [PubMed:
20451693]
69. Simonetti OP, Raman SV. Straining to justify strain measurement. JACC Cardiovasc Imaging
2010;3:152–154. [PubMed: 20159641]
70. Hernando D, Haldar JP, Sutton BP, Ma J, Kellman P, Liang ZP. Joint estimation of water/fat
images and field inhomogeneity map. Magn Reson Med 2008;59:571–580. [PubMed: 18306409]
71. Kellman P, Hernando D, Shah S, Hoyt RF Jr, Kotin RM, Keene BW, Kornegay JN, Aletras AH,
Arai AE. Myocardial fibro-fatty infiltration in Duchenne muscular dystrophy canine model
detected using multi-echo Dixon method of water and fat separation imaging. Proc of Int Soc for
Magn Res Med 2009;17:3761.
72. Wansapura JP, Hor KN, Mazur W, Fleck R, Hagenbuch S, Benson DW, Gottliebson WM. Left
ventricular T2 distribution in Duchenne muscular dystrophy. J Cardiovasc Magn Reson
2010;12:14. [PubMed: 20298602]
73. Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG, Jessup M, Konstam
MA, Mancini DM, Michl K, Oates JA, Rahko PS, Silver MA, Stevenson LW, Yancy CW, Antman
EM, Smith SC Jr, Adams CD, Anderson JL, Faxon DP, Fuster V, Halperin JL, Hiratzka LF,
Jacobs AK, Nishimura R, Ornato JP, Page RL, Riegel B. ACC/AHA 2005 Guideline Update for
the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American
College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing
Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure):
developed in collaboration with the American College of Chest Physicians and the International
Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation
2005;112:e154–235. [PubMed: 16160202]
74. Rosenthal D, Chrisant MR, Edens E, Mahony L, Canter C, Colan S, Dubin A, Lamour J, Ross R,
Shaddy R, Addonizio L, Beerman L, Berger S, Bernstein D, Blume E, Boucek M, Checchia P,
Dipchand A, Drummond-Webb J, Fricker J, Friedman R, Hallowell S, Jaquiss R, Mital S, Pahl E,
Pearce FB, Rhodes L, Rotondo K, Rusconi P, Scheel J, Pal Singh T, Towbin J. International
Verhaert et al. Page 12













Society for Heart and Lung Transplantation: Practice guidelines for management of heart failure in
children. J Heart Lung Transplant 2004;23:1313–1333. [PubMed: 15607659]
75. Chan AK, Sanderson JE, Wang T, Lam W, Yip G, Wang M, Lam YY, Zhang Y, Yeung L, Wu EB,
Chan WW, Wong JT, So N, Yu CM. Aldosterone receptor antagonism induces reverse remodeling
when added to angiotensin receptor blockade in chronic heart failure. J Am Coll Cardiol
2007;50:591–596. [PubMed: 17692742]
76. Duboc D, Meune C, Pierre B, Wahbi K, Eymard B, Toutain A, Berard C, Vaksmann G, Weber S,
Bécane H. Perindopril preventive treatment on mortality in Duchenne muscular dystrophy: 10
years’ follow-up. Am Heart J 2007;154:596–602. [PubMed: 17719312]
77. Prystowsky EN, Pritchett EL, Roses AD, Gallagher J. The natural history of conduction system
disease in myotonic muscular dystrophy as determined by serial electrophysiologic studies.
Circulation 1979;60:1360–1364. [PubMed: 498462]
78. Chien KR. Stress pathways and heart failure. Cell 1999;98:555–558. [PubMed: 10490095]
79. Chien KR. Genotype, phenotype: upstairs, downstairs in the family of cardiomyopathies. J Clin
Invest 2003;111:175–178. [PubMed: 12531871]
Verhaert et al. Page 13













Figure 1. Proteins implicated in the muscular dystrophies
Dystrophin is located inside the cell and bound to actin at its N-terminus and to a large
oligomeric complex of membrane glycoproteins at its C-terminus. This complex, referred to
as the dystrophin-glycoprotein complex (DGC) consists of dystrophin, sarcoglycans (α, β, γ
and δ subunits), α- and β dystroglycan, sarcospan and syntrophins. Mutations in the
dystrophin gene lead to Becker and Duchenne muscular dystrophy. Mutations in the
sarcoglycan subunits cause limb-girdle muscular dystrophy (LGMD). LGMD2I is a distinct
form of LGMD caused by a mutation in the FKRP gene, encoding a Golgi apparatus protein.
FKRP is involved in the glycosylation of α dystroglycan, necessary for its binding to
laminin-α2 and the extracellular matrix.
Mutations in the genes encoding emerin and lamin A/C cause a spectrum of “nuclear
envelopathies”. X-linked and autosomal dominant Emery-Dreifuss muscular dystrophy
belong to this group of diseases, and are both characterized by skeletal muscle wasting,
cardiac conduction defects and cardiomyopathy. Distinct LMNA gene mutations have also
been associated with autosomal dominant limb-girdle muscular dystrophy (LGMD1B) and
with isolated cardiomyopathy and conductive system disease (lamin A/C cardiomyopathy).
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Figure 2. CMR findings in Duchenne muscular dystrophy at different stages of the disease
End-diastolic and end-systolic frames (A, B) from a three-chamber long-axis cine
acquisition (Supplemental Movie I) show preserved LV systolic function in this 28 year-old
male with DMD. Late gadolinium-enhancement images (C: three-chamber view, D: mid-
ventricular short-axis view) in the same patient show that despite preserved global LV
systolic function, myocardial injury is evident as subepicardial fibrosis of the inferolateral
wall (arrowheads). E: LGE in a 14-year old boy with DMD shows more advanced
cardiomyopathy with profound LV dilatation and systolic dysfunction (Supplemental Movie
II), and more extensive subepicardial scarring as well as septal fibrosis in this patient
(arrowheads).
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Figure 3. LGE findings in Becker MD
The pattern of myocardial injury in patients with Becker MD is similar to that seen in DMD,
starting at the subendocardium of the inferolateral wall with an age-dependent increase in
the extent of fibrosis and progressive decline in systolic function. The left and right upper
panels (short-axis and horizontal long-axis views, respectively) show almost transmural
hyperenhancement of the entire anterolateral and inferolateral walls, consistent with
advanced disease. In addition, this patient had also evidence of septal midwall fibrosis
(lower middle panel), also seen in myocarditis and other non-ischemic cardiomyopathies.
Verhaert et al. Page 16













Figure 4. Cardiomyopathy in a female Duchenne carrier
Coronary angiography and CMR findings in a 58-year old female patient with Duchenne
carrier status and chronic heart failure. Upper panels: In spite of normal findings by
coronary angiography, transmural scarring of the inferolateral wall is evident by LGE
(yellow arrowheads). Lower panels: CMR cine imaging showed severe global biventricular
systolic dysfunction, with severe LV dilatation and akinesis of the inferolateral walls.
Displacement of the papillary muscles due to global LV dilatation and segmental bulging of
the inferolateral wall (white arrowheads) caused severe mitral regurgitation (green arrows,
velocity-encoded cine image, lower right panel).
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Figure 5. CMR findings in lamin A/C cardiomyopathy
Lamin A/C cardiomyopathy has been associated with midwall fibrosis of the mid-ventricular
septum (left panel, red arrow) at an early stage of the disease. Note also the presence of
fibrosis at the RV-LV septal insertion sites (yellow arrowheads) in this patient. Unlike
patients with different types of LMNA-mutations (EMDM, LGMDB1), lamin A/C
cardiomyopathy does not typically produce apparent skeletal muscle weakness.
Nevertheless, muscle imaging in these patients may reveal fibrosis of the gastrocnemius
muscles (right panel, arrows), suggesting a continuum in the LMNA-gene disorders between
phenotypes with selective cardiac involvement and phenotypes with both cardiac and
skeletal muscle abnormalities.
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Figure 6. Late gadolinium-enhancement findings in LGMD2I
Upper panels: LGE in an 11-year old boy with FKRP mutation. Despite normal LV systolic
function, midwall fibrosis of the septum and inferior wall was seen, consistent with early
cardiac involvement.
Lower panels: LGE in 57-year old patient with FKRP mutation. At an advanced stage of the
disease, patients with LGMD2I may develop cardiomyopathy with severe systolic
dysfunction and extensive scarring of the lateral walls (yellow arrowheads). The septum is
affected as well in this patient (red arrows).
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Figure 7. Fat infiltration vs. gadolinium enhancement in dystrophin-associated cardiomyopathy
Left: Late gadolinium enhancement image acquired in the three-chamber plane shows
prominent enhancement of the basal inferolateral wall in a patient with Duchenne muscular
dystrophy. Middle: Fat-only reconstruction using the multi-echo Dixon method of water and
fat separation magnetic resonance imaging shows a thin rim of epimyocardial fat, whereas
the corresponding water-only reconstruction shows more extensive hyperenhancement;
together, these images suggest a combination of fibrofatty replacement of normal
myocardium in this disorder.
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